plasmaMATCH (CRUK/15/010): Evaluation of Circulating Tumor DNA Testing to Direct Targeted Therapies in Patients with Advanced Breast Cancer

December 10-14, 2019; San Antonio, Texas
Patients with advanced breast cancer and rare mutations identified by ctDNA testing responded to matched targeted therapies.
Format: Microsoft PowerPoint (.ppt)
File Size: 211 KB
Released: December 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Daiichi Sankyo, Inc.
Genentech
Merck Sharp & Dohme Corp
Puma Biotechnology
Seattle Genetics

Related Content

Expert commentary featuring recommendations on preserving continuity of care and ensuring safety for patients with advanced breast cancer during the COVID-19 pandemic

Hope S. Rugo, MD Released: September 25, 2020

Downloadable summary slides with quick expert analysis of the optimal management of patients with HER2-positive metastatic breast cancer, from Clinical Care Options.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: September 23, 2020

Read this commentary from Clinical Care Options to gain expert perspectives on PARP inhibition in early, metastatic, and triple-negative breast cancer.

Mark E. Robson, MD Released: September 22, 2020

On-demand Webcast featuring expert discussion of new therapies for relapsed/refractory HER2-positive metastatic breast cancer, from a live CCO Webinar

Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD person default Cristina Saura, MD, PhD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 11, 2020 Expired: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue